Richard Casaburi1, Junko Nakata1, Lawrence Bistrong1, Edwardo Torres1, Mehdi Rambod1,2, Janos Porszasz1. 1. Rehabilitation Clinical Trials Center, Los Angeles Biomedical Research Institute at Harbor-University of California, Los Angeles Medical Center, Torrance. 2. Division of Cardiology, University of Vermont College of Medicine, Burlington.
Abstract
Background: Underweight chronic obstructive pulmonary disease (COPD) patients with involuntary weight loss have a poor prognosis; no effective therapy is currently available. We conducted the first clinical trial seeking to determine whether combination therapy with an appetite stimulant and an anabolic steroid would have beneficial effects on body composition for patients with COPD cachexia. Methods: We conducted a 12-week pilot study in which 4 men and 5 women (age 64±10 y, forced expiratory volume in 1 second [FEV1] 31±9 %pred., body mass index [BMI] 18±3 kg/m2) with low-normal testosterone levels (average 532±45ng/dl in men and 12.4±5.3ng/dl in women) and weight loss ≥10 lbs over the previous year were treated with oral megestrol acetate 800mg/day plus weekly testosterone enanthate injections, initially 125 mg in men and 40 mg in women, with doses subsequently adjusted targeting circulating nadir testosterone levels of 850 and 300 ng/dl, respectively. Results: On treatment, nadir testosterone level increases averaged 160±250 ng/dl (NS) in men and 322±49 (p<0.001) ng/dl in women. Body weight increased in all individuals, with average end-intervention weight gain of 3.1±2.2 kg (p<0.005). Two women and 2 men had COPD exacerbations and did not complete the 12-week study. In the 5 individuals who completed, dual energy x ray absorptiometry (DEXA) scans revealed an average 2.0±1.5 kg lean mass and 2.3±1.7 kg fat mass increase (each p<0.05). No adverse effects of treatment were detected. Conclusions: Combination therapy reversed the trajectory of involuntary weight loss and increased lean mass in cachectic COPD patients. Though the interventions were apparently well tolerated, participant drop-out rate was high. Larger randomized placebo-controlled long-term studies with functional outcomes are needed.
RCT Entities:
Background: Underweight chronic obstructive pulmonary disease (COPD) patients with involuntary weight loss have a poor prognosis; no effective therapy is currently available. We conducted the first clinical trial seeking to determine whether combination therapy with an appetite stimulant and an anabolic steroid would have beneficial effects on body composition for patients with COPD cachexia. Methods: We conducted a 12-week pilot study in which 4 men and 5 women (age 64±10 y, forced expiratory volume in 1 second [FEV1] 31±9 %pred., body mass index [BMI] 18±3 kg/m2) with low-normal testosterone levels (average 532±45ng/dl in men and 12.4±5.3ng/dl in women) and weight loss ≥10 lbs over the previous year were treated with oral megestrol acetate 800mg/day plus weekly testosterone enanthate injections, initially 125 mg in men and 40 mg in women, with doses subsequently adjusted targeting circulating nadirtestosterone levels of 850 and 300 ng/dl, respectively. Results: On treatment, nadirtestosterone level increases averaged 160±250 ng/dl (NS) in men and 322±49 (p<0.001) ng/dl in women. Body weight increased in all individuals, with average end-intervention weight gain of 3.1±2.2 kg (p<0.005). Two women and 2 men had COPD exacerbations and did not complete the 12-week study. In the 5 individuals who completed, dual energy x ray absorptiometry (DEXA) scans revealed an average 2.0±1.5 kg lean mass and 2.3±1.7 kg fat mass increase (each p<0.05). No adverse effects of treatment were detected. Conclusions: Combination therapy reversed the trajectory of involuntary weight loss and increased lean mass in cachectic COPDpatients. Though the interventions were apparently well tolerated, participant drop-out rate was high. Larger randomized placebo-controlled long-term studies with functional outcomes are needed.
Entities:
Keywords:
body composition; cachexia; chronic obstructive pulmonary disease; megesterol; testosterone
Authors: Annemie M W J Schols; Roelinka Broekhuizen; Clarie A Weling-Scheepers; Emiel F Wouters Journal: Am J Clin Nutr Date: 2005-07 Impact factor: 7.045
Authors: Friedrich Koehler; Wolfram Doehner; Soeren Hoernig; Christian Witt; Stefan D Anker; Matthias John Journal: Int J Cardiol Date: 2006-10-24 Impact factor: 4.164
Authors: Charles P Lambert; Dennis H Sullivan; Scott A Freeling; Diana M Lindquist; William J Evans Journal: J Clin Endocrinol Metab Date: 2002-05 Impact factor: 5.958
Authors: Shalender Bhasin; Linda Woodhouse; Richard Casaburi; Atam B Singh; Ricky Phong Mac; Martin Lee; Kevin E Yarasheski; Indrani Sinha-Hikim; Connie Dzekov; Jeanne Dzekov; Lynne Magliano; Thomas W Storer Journal: J Clin Endocrinol Metab Date: 2004-11-23 Impact factor: 5.958
Authors: Erica P A Rutten; Peter M A Calverley; Richard Casaburi; Alvar Agusti; Per Bakke; Bartolome Celli; Harvey O Coxson; Courtney Crim; David A Lomas; William Macnee; Bruce E Miller; Stephan I Rennard; Paul D Scanlon; Edwin K Silverman; Ruth Tal-Singer; Jørgen Vestbo; Michael L Watkins; Emiel F M Wouters Journal: Ann Nutr Metab Date: 2013-11-07 Impact factor: 3.374
Authors: Alexander E Weber; Matthew C Gallo; Ioanna K Bolia; Emmett J Cleary; Todd E Schroeder; George F Rick Hatch Journal: J Am Acad Orthop Surg Glob Res Rev Date: 2022-01-04